Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...

Arrowhead Pharmaceuticals recently announced that Health Canada issued a Notice of Compliance for REDEMPLO (plozasiran) as an ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

Since the identification of the double-helix structure of DNA, the scientific field of genetics has developed and found applications in many diverse industries. First discovered in the late 1990s, ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...